Lilly CEO Sees Foundayo Growth Accelerating as International Launch Expands
LLY sits 64% above its 52-week low of $712.05 on light trading volume (0.4× avg).
Summary
Eli Lilly CEO David Ricks said Foundayo (orforglipron) is now in four or five foreign markets with many more expected in the next six months, calling international expansion a big part of the oral GLP-1 story due to manufacturing capacity. He spoke at the groundbreaking of a new $6.5B Houston site that will produce raw materials for Foundayo and other small molecules, opening in 2030. Ricks repeated that Foundayo has captured about one in three new oral obesity pill prescriptions, increasing week over week, and noted about 70% of the 700,000 seniors who received a GLP-1 prescription since July 1 are on a Lilly drug. Foundayo could also gain a type 2 diabetes indication by year-end. This follows the ACHIEVE-3 trial in June showing Foundayo bested Novo Nordisk's oral semaglutide on A1C and weight loss. The commentary reinforces Lilly's competitive position in the oral obesity market against Novo Nordisk, with international rollout and manufacturing scale as key growth drivers.
At the time of this announcement, LLY was trading at $1,168.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.